December 17, 2024 09:59 AM EST
R&D

UCB, No­var­tis say a Phase 2a Parkin­son's study failed

Max Gelman

Senior Editor

UCB and No­var­tis end­ed de­vel­op­ment on the lead pro­gram in their part­ner­ship af­ter re­port­ing a Phase 2a fail­ure in Parkin­son’s dis­ease.

The com­pa­nies

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Chica­go’s biotech scene is grow­ing up. What’s fu­el­ing it?

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Pfiz­er’s mes­sage to in­vestors: The ship is steady­ing in 2025 (even if Wash­ing­ton is tur­bu­lent)

Jazz Phar­ma­ceu­ti­cals CEO and co-founder Bruce Cozadd is re­tir­ing

Mer­ck winds down TIG­IT, LAG-3 pro­grams meant to tem­per Keytru­da ero­sion

A service from the Financial Times